🇺🇸 Amlodipine camsylate in United States

34 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 34

Most-reported reactions

1. Off Label Use — 6 reports (17.65%)
2. Fall — 5 reports (14.71%)
3. Multiple Drug Therapy — 5 reports (14.71%)
4. Abdominal Pain — 3 reports (8.82%)
5. Acute Kidney Injury — 3 reports (8.82%)
6. Haematochezia — 3 reports (8.82%)
7. Pyrexia — 3 reports (8.82%)
8. Clostridium Difficile Infection — 2 reports (5.88%)
9. Decreased Appetite — 2 reports (5.88%)
10. Duodenal Ulcer — 2 reports (5.88%)

Source database →

Frequently asked questions

Is Amlodipine camsylate approved in United States?

Amlodipine camsylate does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Amlodipine camsylate in United States?

Organon and Co is the originator. The local marketing authorisation holder may differ — check the official source linked above.